Table 1.
Baseline Characteristics of Subjects with fILD
| fILD N=54 |
||
|---|---|---|
| Demographics | ||
| Age in years | 69.2±7.0 | 69.0 (65.0–75.0) |
| Male, % | 65 | |
| BMI | 30.4±6.9 | 29.9 (25.8–33.1) |
| Lung disease data | ||
| FVC% | 64.0±15.9 | 64.0 (52.0–74.0) |
| DLCO% | 43.4±16.5 | 44.0 (29.0–55.0) |
| ILD Dx, N | ||
| Asbestosis | 2 | |
| cHP | 3 | |
| fFIP | 6 | |
| fNSIP | 19 | |
| IPF | 22 | |
| fSarcoidosis | 1 | |
| ILD Tx, N | ||
| None | 48 | |
| Azathioprine | 4 | |
| Mycophenolate mofetil | 1 | |
| Cyclophosphamide | 1 | |
| On prednisone, % | 25 | |
| Supplemental oxygen, N | ||
| 24hrs | 17 | |
| Exertion and sleep | 4 | |
| None | 33 | |
| Sleep data | ||
| Has OSA | ||
| 5 < AHI ≤ 15 | 15 | |
| 15 < AHI ≤ 30 | 6 | |
| AHI > 30 | 14 | |
| AHI | 23.7±31.2 | 10.8 (2.5–31.2) |
| Nadir SpO2 during PSG | 77.5±8.9 | 79.0 (74.0–83.0) |
| Epworth Sleepiness Scale (ESS)* | 7.9±3.6 | 9.0 (5.0–10.0) |
| ESS > 9, %* | 37 | |
| % with ESS > 9 and OSA | 72 | |
| GERD data | ||
| GERD symptoms, % | 17 | |
| On Daily Anti-reflux Tx, % | 44 | |
| On PPI during pH probe, % | 21 | |
Data are mean±standard deviation, median (interquartile range), other values are percentages or proportions; fILD=fibrotic interstitial lung disease; BMI=body mass index; FVC%=percent predicted forced vital capacity; DLCO%=percent predicted diffusing capacity of the lung for carbon monoxide; ILD=interstitial lung disease; Dx=diagnosis; cHP=chronic hypersensitivity pneumonitis; fFIP=fibrotic familial interstitial pneumonia; fNSIP=fibrotic nonspecific interstitial pneumonia; Tx=medication; OSA=obstructive sleep apnea; AHI=apnea hypopnea index;
N=49 subjects with fILD; PSG=polysomnogram; SpO2=peripheral oxygen saturation; ESS=Epworth Sleepiness Scale; GERD=gastroesophageal reflux disease; Tx=treatment; PPI=proton pump inhibitor